Publications by authors named "Dale R Miles"

Claim this Profile
M
Mitigating ipatasertib-induced glucose increase through dose and meal timing modifications.
Dhruvitkumar S Sutaria, Priya Agarwal, Kuan-Chieh Huang, Dale R Miles, Jacob Rotmensch

Clin Transl Sci· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Pharmacology Perspectives for Adoptive Cell Therapies in Oncology.
Weize Huang, Junyi Li, Michael Z Liao, Stephanie N Liu, Jiajie Yu, Dale R Miles

Clin Pharmacol Ther· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of cabozantinib treatment on QT interval in a phase 3 study in medullary thyroid cancer: evaluation of indirect QT effects mediated through treatment-induced changes in serum electrolytes.
Dale R Miles, Steven A Lacy, David R Wada, Steve Milwee, Yifah Yaron

Cancer Chemother Pharmacol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib.
Steven A Lacy, Dale R Miles, Linh T Nguyen

Clin Pharmacokinet· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer.
Heather A Wakelee, Scott Gettinger, Jeffrey Engelman, Pasi A Jänne, Howard West, Dale R Miles

Cancer Chemother Pharmacol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic/pharmacodynamic modeling of tumor growth kinetics in medullary thyroid cancer patients receiving cabozantinib.
Dale R Miles, David R Wada, Nelson L Jumbe, Steven A Lacy, Linh T Nguyen

Anticancer Drugs· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation and use of three complementary analytical methods (LC-FLS, LC-MS/MS and ICP-MS) to evaluate the pharmacokinetics, biodistribution and stability of motexafin gadolinium in plasma and tissues.
Dale R Miles, Mimi Mesfin, Tarak D Mody, Mark Stiles, Jean Lee

Anal Bioanal Chem· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reductase-mediated metabolism of motexafin gadolinium (Xcytrin) in rat and human liver subcellular fractions and purified enzyme preparations.
Chitra Mani, Shubhra Upadhyay, Steve Lacy, Garry W Boswell, Dale R Miles

J Pharm Sci· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of motexafin gadolinium in adults with brain metastases or glioblastoma multiforme.
Dale R Miles, Jennifer A Smith, See-Chun Phan, Sammy J Hutcheson, Markus F Renschler

J Clin Pharmacol· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis